請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/89797完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 王振泰 | zh_TW |
| dc.contributor.advisor | Jann-Tay Wang | en |
| dc.contributor.author | 陳意潔 | zh_TW |
| dc.contributor.author | Yi-Jie Chen | en |
| dc.date.accessioned | 2023-09-22T16:09:25Z | - |
| dc.date.available | 2023-11-09 | - |
| dc.date.copyright | 2023-09-22 | - |
| dc.date.issued | 2023 | - |
| dc.date.submitted | 2023-07-20 | - |
| dc.identifier.citation | [1] Cochrane risk of bias tool (RoB). https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials. Accessed 31 Jan 2021
[2] Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41. https://doi:10.1159/000180580 [3] Gomez-Simmonds, A., Nelson, B., Eiras, D. P., Loo, A., Jenkins, S. G., Whittier, S., Calfee, D. P., Satlin, M. J., Kubin, C. J., & Furuya, E. Y. (2016). Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections. Antimicrobial agents and chemotherapy, 60(6), 3601–3607. https://doi.org/10.1128/AAC.03007-15 [4] Hartzell, J. D., Neff, R., Ake, J., Howard, R., Olson, S., Paolino, K., Vishnepolsky, M., Weintrob, A., & Wortmann, G. (2009). Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 48(12), 1724–1728. https://doi.org/10.1086/599225 [5] Hou, S. Y., Wu, D., & Feng, X. H. (2020). Polymyxin monotherapy versus polymyxin-based combination therapy against carbapenem-resistant Klebsiella pneumoniae: A systematic review and meta-analysis. Journal of global antimicrobial resistance, 23, 197–202. https://doi.org/10.1016/j.jgar.2020.08.024 [6] Motsch, J., Murta de Oliveira, C., Stus, V., Köksal, I., Lyulko, O., et al. (2020). RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 70(9), 1799–1808. https://doi.org/10.1093/cid/ciz530 [7] Newcastle-Ottawa Scale (NOS). http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 31 Jan 2021 [8] PA Harris, R Taylor, BL Minor, V Elliott, M Fernandez, L O’Neal, L McLeod, G Delacqua, F Delacqua, J Kirby, SN Duda, REDCap Consortium, The REDCap consortium: Building an international community of software partners, J Biomed Inform. 2019 May 9. https://doi: 10.1016/j.jbi.2019.103208 [9] PA Harris, R Taylor, R Thielke, J Payne, N Gonzalez, JG. Conde, Research electronic data capture (REDCap) – A metadata-driven methodology and workflow process for providing translational research informatics support, J Biomed Inform. 2009 Apr;42(2):377-81. [10] Papp-Wallace, K. M., Endimiani, A., Taracila, M. A., & Bonomo, R. A. (2011). Carbapenems: past, present, and future. Antimicrobial agents and chemotherapy, 55(11), 4943–4960. https://doi.org/10.1128/AAC.00296-11 [11] Paul, M., Daikos, G. L., Durante-Mangoni, E., Yahav, D., et al. (2018). Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. The Lancet. Infectious diseases, 18(4), 391–400. https://doi.org/10.1016/S1473-3099(18)30099-9 [12] PRISMA statement. http://www.prisma-statement.org/PRISMAStatement/PRISMAStatement. Accessed 30 Dec 2021 [13] Research Electronic Data Capture (REDCap). CITATIONS. Available from: https://projectredcap.org/resources/citations/ (Accessed 01 Aug 2022) [14] ReviewManager (RevMan). https://training.cochrane.org/online-learning/core-software-cochrane-reviews/revman. Accessed 31 Jan 2021 [15] Sealed Envelope Ltd. 2012. Power calculator for binary outcome non-inferiority trial. Available from: https://www.sealedenvelope.com/power/binary-superiority/ (Accessed 01 August 2022). [16] Sheu, C. C., Chang, Y. T., Lin, S. Y., Chen, Y. H., & Hsueh, P. R. (2019). Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options. Frontiers in microbiology, 10, 80. https://doi.org/10.3389/fmicb.2019.00080 [17] Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–810. https://doi:10.1001/jama.2016.0287 [18] Stein, G. E., & Babinchak, T. (2013). Tigecycline: an update. Diagnostic microbiology and infectious disease, 75(4), 331–336. https://doi.org/10.1016/j.diagmicrobio.2012.12.004 [19] The World Health Organization. Antibiotic resistance. https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance. Accessed 30 Nov 2021 [20] U.S. Food and Drug Administration. CFR - Code of Federal Regulations Title 21. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=312.32 (Accessed 01 Aug 2022) [21] van Duin, D., & Doi, Y. (2017). The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence, 8(4), 460–469. https://doi.org/10.1080/21505594.2016.1222343 [22] van Duin, D., & Paterson, D. L. (2016). Multidrug-Resistant Bacteria in the Community: Trends and Lessons Learned. Infectious disease clinics of North America, 30(2), 377–390. https://doi.org/10.1016/j.idc.2016.02.004 [23] van Duin, D., & Paterson, D. L. (2020). Multidrug-Resistant Bacteria in the Community: An Update. Infectious disease clinics of North America, 34(4), 709–722. https://doi.org/10.1016/j.idc.2020.08.002 [24] Yohei Doi, Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections, Clinical Infectious Diseases, Volume 69, Issue Supplement_7, 1 December 2019, Pages S565–S575. https://doi.org/10.1093/cid/ciz830 [25] Kaye, K. S., Marchaim, D., Thamlikitkul, V., Carmeli, Y., Chiu, C.-H., et al. (2023). Colistin monotherapy versus combination therapy for carbapenem-resistant organisms. NEJM Evidence, 2(1). https://doi.org/10.1056/evidoa2200131 [26] Hao M, Yang Y, Guo Y, Wu S, Hu F, Qin X. Combination Regimens with Colistin Sulfate versus Colistin Sulfate Monotherapy in the Treatment of Infections Caused by Carbapenem-Resistant Gram-Negative Bacilli. Antibiotics. 2022; 11(10):1440. https://doi.org/10.3390/antibiotics11101440 [27] Sy CL, Chen PY, Cheng CW, et al. Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms. J Microbiol Immunol Infect. 2022;55(3):359-386. https://doi:10.1016/j.jmii.2022.02.001 [28] Taiwan Centers for Disease Control. Available from: https://www.cdc.gov.tw/Category/MPage/4G8HuDdUN1k4xaBJhbPzKQ (Accessed 01 Aug 2022) [29] Jean SS, Lee NY, Tang HJ, Lu MC, Ko WC, Hsueh PR. Carbapenem-Resistant Enterobacteriaceae Infections: Taiwan Aspects. Front Microbiol. 2018;9:2888. Published 2018 Nov 27. https://doi:10.3389/fmicb.2018.02888 [30] Abdelsalam MFA, Abdalla MS, El-Abhar HSE. Prospective, comparative clinical study between high-dose colistin monotherapy and colistin-meropenem combination therapy for treatment of hospital-acquired pneumonia and ventilator-associated pneumonia caused by multidrug-resistant Klebsiella pneumoniae. J Glob Antimicrob Resist. 2018;15:127-135. https://doi:10.1016/j.jgar.2018.07.003 [31] Ardebili A, Izanloo A, Rastegar M. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?. Expert Rev Anti Infect Ther. 2023;21(4):387-429. https://doi:10.1080/14787210.2023.2184346 [32] ICH. Efficacy Guidelines. Available from: https://www.ich.org/page/efficacy-guidelines (Accessed 01 Aug 2022) [33] Zhang L, Zhen S, Shen Y, et al. Bloodstream infections due to Carbapenem-Resistant Enterobacteriaceae in hematological patients: assessment of risk factors for mortality and treatment options. Ann Clin Microbiol Antimicrob. 2023;22(1):41. Published 2023 May 18. https://doi:10.1186/s12941-023-00586-y | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/89797 | - |
| dc.description.abstract | 背景
碳青黴醯類抗生素通常被認為是治療多重抗藥性微生物的最後一道防線，由於碳青黴醯類抗藥性腸道菌的廣泛傳播，以致臨床治療上能使用的藥物有限。在台灣，多黏菌素（polymixin）是針對具碳青黴醯抗藥性腸道菌（carbapenem-resistant Enterobacteriaceae, CRE）感染的首選藥物之一。然而，比較使用多粘菌素合併carbapenem類微生物製劑之合併治療，與單一使用多粘菌素治療 CRE感染的臨床療效之研究，目前仍然有限。因此，本研究以系統性文獻回顧與統合分析方式，探討治療具CRE感染使用多粘菌素合併治療與單一治療之比較。 方法 本研究利用電子資料庫進行主題相關文獻檢索，針對CRE感染，比較使用多粘菌素合併carbapenem類微生物製劑之合併治療，或是單一使用多粘菌素治療之30 天全因死亡率（all-cause mortality）。將符合納入條件的文獻進行資料品質評估，並提取數據整理合併後，使用隨機效應模型估計匯總優勢比（odds ratio, OR）。 結果 根據研究方法，最終選擇了五項文獻共計330名受試者納入統合分析。在30 天之全因死亡率，針對使用多粘菌素的合併治療或是單一使用多粘菌素治療CRE感染，統計上具有顯著差異（pooled OR, 0.53; 95% CI 0.28-1.00, p=0.05）。異質性低（I2=0%）。 結論 本統合分析結果顯示，使用多粘菌素的合併治療或是單一使用多粘菌素治療CRE感染在30天之全因死亡率在統計上具顯著性的差異。然而，本研究結果仍存在許多限制，例如納入的研究族群具有異質性、致病原不同，以及治療策略不同，故依據結果設計了一項具規模性的多中心臨床試驗計畫書。 | zh_TW |
| dc.description.abstract | Background
Carbapenems use to be considered as the last-line defense against multidrug-resistant microorganisms. The spread of carbapenem-resistant Enterobacteriaceae (CRE) results in the challenge of limited active drugs. In Taiwan, colistin, which belongs to the polymyxin class, is a prominent medication utilized for treating infections caused by CRE. However, studies to compare to the clinical effectiveness of polymyxin-based combination therapy or polymyxin-based monotherapy on treatment for CRE infection are still rare. Therefore, we conducted this meta-analysis to address the effectiveness compared with polymyxin-based combination therapy for treating CRE infection. Methods A systematic literature review and meta-analysis were performed by searched electronic publishing to compare the clinical effectiveness of polymyxin-based combination therapy or polymyxin monotherapy on treatment for CRE infection. The primary outcome was 30-day all-cause mortality. Data was retrieved from included studies that met all eligibility criteria and quality assessment. The pooled odds ratio (OR) was estimated using a random-effect model. Results A total of five studies containing 330 subjects were selected for the meta-analysis. The pooling result shows that combination therapy was significantly better than monotherapy (OR, 0.53; 95% CI 0.28-1.00, p=0.05). Heterogeneity was low (I2=0%). Conclusion The present study demonstrated that there is significant difference between the combination therapy group and the monotherapy group in 30-day mortality. Our study has several limitations, such us study populations are heterogeneous, the pathogens are different, and the dosing strategies are different. Hence, a well-designed, large-scaled RCT comparing polymyxin-based combination therapy versus polymyxin-based monotherapy is indicated. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2023-09-22T16:09:25Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2023-09-22T16:09:25Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | 口試委員會審定書 I
誌謝 II 中文摘要 IV ABSTRACT V TABLE OF CONTENTS VII LIST OF ABBREVIATIONS X INTRODUCTION 1 METHODS 3 RESULTS 5 DISCUSSION 7 CONCLUSION 9 APPENDIX: CLINICAL STUDY PROTOCOL 19 PROTOCOL SYNOPSIS 20 1. STUDY BACKGROUND 21 2. STUDY DESIGN 23 3. STUDY POPULATION 23 3.1 Definition of CRE bacteremia 23 3.2 Inclusion Criteria 24 3.3 Exclusion Criteria 24 3.4 Randomization and Treatment Group Assignment 25 4. STUDY TREATMENT 25 4.1 Blinding 25 4.2 Study Drugs 25 4.3 Administration 25 4.4 Dose Modification 26 4.5 Prior and Concomitant Medications and Treatments 27 5. STUDY PROCEDURES 27 5.1 Screening and Enrollment (Day -1 to 1) 30 5.2 Treatment Period 31 5.2.1. Treatment Day 1 (Base-line procedure and Day 1 of Treatment, Visit 1) 31 5.2.2. Treatment Day 2 to Day 7 (up to Day 14 if clinically indicated, Visit 2-14) 31 5.3 End of Treatment (withing 24 hours after last infusion) 33 5.4 End of Study (EOS, Day 30±3 days) 33 5.5 Early Termination (ET) 33 5.6 Study Discontinuation and Subject Withdrawal 34 6. STUDY ASSESSMENTS AND EVALUATION 35 6.1 Physical Examination 35 6.2 Clinical Laboratory Assessments 35 6.3 Clinical Assessment and Outcome 37 6.4 Microbiologic Assessment and Outcome 38 6.5 Severity of CRE bacteremia 39 7. ADVERSE EVENT AND ADVERSE DRUG REACTION MONITORING 40 8. DATA MANAGEMENT 43 9. STATISTICAL CONSIDERATIONS 44 10. PROTECTION OF HUMAN SUBJECTS 45 11. REFERENCES 46 | - |
| dc.language.iso | en | - |
| dc.subject | 碳青黴醯抗藥性腸道菌 | zh_TW |
| dc.subject | 合併治療 | zh_TW |
| dc.subject | 多黏菌素 | zh_TW |
| dc.subject | 單一治療 | zh_TW |
| dc.subject | 統合分析 | zh_TW |
| dc.subject | polymyxin | en |
| dc.subject | combination therapy | en |
| dc.subject | monotherapy | en |
| dc.subject | carbapenem-resistant Enterobacteriaceae | en |
| dc.subject | meta-analysis | en |
| dc.title | 使用Polymyxin合併其他抗生素治療或Polymyxin單一治療Carbapenem-resistant Enterobacteriaceae之結果比較：統合分析與臨床試驗計畫書 | zh_TW |
| dc.title | Outcomes Comparison between Polymyxin-based Combination Therapy and Polymyxin Monotherapy for Carbapenem-resistant Enterobacteriaceae: A Systematic Review and Meta-analysis and Clinical Study Protocol | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 111-2 | - |
| dc.description.degree | 碩士 | - |
| dc.contributor.oralexamcommittee | 方啓泰;陳抱宇 | zh_TW |
| dc.contributor.oralexamcommittee | Chi-Tai Fang;Pao-Yu Chen | en |
| dc.subject.keyword | 碳青黴醯抗藥性腸道菌,多黏菌素,合併治療,單一治療,統合分析, | zh_TW |
| dc.subject.keyword | carbapenem-resistant Enterobacteriaceae,polymyxin,combination therapy,monotherapy,meta-analysis, | en |
| dc.relation.page | 50 | - |
| dc.identifier.doi | 10.6342/NTU202301801 | - |
| dc.rights.note | 同意授權(限校園內公開) | - |
| dc.date.accepted | 2023-07-20 | - |
| dc.contributor.author-college | 醫學院 | - |
| dc.contributor.author-dept | 臨床醫學研究所 | - |
| 顯示於系所單位： | 臨床醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-111-2.pdf 授權僅限NTU校內IP使用（校園外請利用VPN校外連線服務） | 1.22 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。